Asmuth, David M <br/><br/>
Gastrointestinal-associated lymphoid tissue immune reconstitution in a randomized clinical trial of raltegravir versus non-nucleoside reverse transcriptase inhibitor-based regimens.  [electronic resource] 

 -  AIDS (London, England)  Aug 2012 
 - 1625-34 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1473-5571 
<br/><br/><label>Standard No.: </label>10.1097/QAD.0b013e3283546595  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Acquired Immunodeficiency Syndrome--drug therapy<br/>Anti-HIV Agents--immunology<br/>CD4 Lymphocyte Count<br/>CD4-Positive T-Lymphocytes--drug effects<br/>CD8-Positive T-Lymphocytes--drug effects<br/>Drug Therapy, Combination<br/>Endoscopy<br/>Female<br/>Gastrointestinal Tract--immunology<br/>Humans<br/>Immune Reconstitution Inflammatory Syndrome--chemically induced<br/>Immunohistochemistry<br/>Lymphocyte Activation<br/>Lymphoid Tissue--immunology<br/>Male<br/>Nevirapine--therapeutic use<br/>Nitriles<br/>Pyridazines--therapeutic use<br/>Pyrimidines<br/>Pyrrolidinones--therapeutic use<br/>RNA, Viral<br/>Raltegravir Potassium<br/>Reverse Transcriptase Inhibitors--therapeutic use<br/>Viral Load